NCBiotech News

A Raleigh biotechnology startup is putting an initial $26 million investment into the establishment of a teamwork approach to enhance efficiencies for cell- and gene-based cancer therapy developers.

Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical trials of potential therapies for two inherited blood disorders after clearance from the FDA.

GRAIL's new blood test that can detect more than 50 types of cancer in a single blood draw is now available in the United States with a prescription.

Shanghai-based cancer immunotherapy innovator CARsgen has announced plans to invest $157 million to establish a Durham site that will employ 200 people over the next few years.

A trio of Triangle scientists is launching Isolere Bio, bootstrapped with a $250K NCBiotech loan that led to $7 million in seed funding attracted by the technology they believe can allow gene therapy companies to vastly increase the number of doses they can produce.

UNC-affiliated startup RainBio is parlaying support from NCBiotech to develop a novel gene therapy for corneal blindness, giving patients a chance not only for longer lives, but better ones.

San Francisco-based medical genetics testing company Invitae is investing $114.6 million to bring its wide-ranging medical testing capabi

Register now to participate in two free virtual events that will discuss the latest advancements in cell- and gene-based therapy and North Carolina’s growing global reputation for development and advancement of these therapeutics.

bluebird bio has hit a major milestone, garnering U.S. Food and Drug Administration approval to market its first product in the U.S., which is also its first cell therapy designed to treat cancer. It's partnered with Bristol Myers on the product launch.

Baebies, a Durham company specializing in disorder screening for newborns, has reached a milestone of 10 million tests delivered to labs since its founding in 2014 was bootstrapped by an early loan from the North Carolina Biotechnology Center.

Morrisville gene editing startup Locus Biosciences has completed the world’s first clinical trial of a recombinant bacteriophage therapy that also marks the first time a CRISPR-enhanced therapeutic has been administered in a clinical setting.

Durham's Precision Biosciences has received FDA approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.

Atsena Therapeutics is a Durham clinical-stage gene therapy company with $63M in the bank so far to propel its mission to reverse and prevent blindness.

California gene therapy innovator Adverum Biotechnologies announced plans today to invest some $83 million to establish a manufacturing site in Durham that will employ 202 people through 2026.

Ribometrix, a Durham company specializing in RNA-based therapeutics, has formed a drug discovery and development collaboration with Genentech that could be worth more than $1 billion.